摘要
目的：以琥珀酸索利那新（ Solifenacin）与酒石酸托特罗定（ Tolterodine）为研究对象，探讨新型抗胆碱能药物女性膀胱过度活动症的疗效及副作用。方法：选择2010年1月-2013年10月期间，我院确诊为女性膀胱过度活动症的患者，采用随机方法分为A组和B组。 A组患者给予琥珀酸索利那新5mg，口服1次／d，治疗时间均为4周。 B组患者口服酒石酸托特罗定片，每天口服2次，每次2 mg，疗程连续服用4周；治疗期间停用其它解痉药物；治疗前后均记录患者IPSS 评分、初尿意膀胱容量、最大膀胱容量，并记录治疗后发生发口干、便秘、嗜睡和视物模糊等副作用的数量。结果：20例患者随访时间8周，治疗后IPSS 评分下降，初尿意膀胱容量及最大膀胱容量上升，治疗后和治疗前相比，具有显著性差异（ P ＜0．05）；组间比较无明显差异（ P＞0．05）。但是副作用发生种类和数量经x2检验有明显差异（P ＜0．05）。结论：琥珀酸索利那新（卫喜康）与酒石酸托特罗定抗胆碱能药物均是治疗女性膀胱过度活动症的有效方法，二者比较在疗效方面无明显差异，但是在副反应的发生方面存在差异，提示琥珀酸索利那新具有更好的耐受性。
Objective：To investigate the effects of Solifenacin and Tolterodine on the female overactive bladder.Methods：During Jan.2012 and Oct.2013,20 female patients with overactive bladder were chosen and randomly divided into 2 groups （ group A and group B ,each group n=10）.Group A were treated by Solifenacin,5mg once per day.Group B were treated by Tolterodine, 2mg twice per day. Both groups stopped treating 4 weeks later .t was requested to record patients＇I-PSS, initial micturition desire bladder capacity, maxi-mum bladder capacity in the pre-therapy and the 4th week, 8th week of post-therapy.The symptoms of side effects ,such as dry thirst ,constipation ,sleepy were recorded .Results：Compared with the pre-therapy, both groups were characterized by the reduction of IPPS value（P〈0.05）,increment of initial micturition desire bladder capacity（P〈0.05）and maximum bladder capacity（P〈0.05）in the 8th week.But there were differences in the kinds and numbers of symptoms about side effects between two groups （P〈0.05）.Conclusions：The results presented that these were effective methods of oral Solifenacin and Tolterodine in the treatment of female overactive bladder. Further, Solifenacin should be more acceptable because of less side effects.
出处
《中国伤残医学》
2015年第10期16-18,共3页
Chinese Journal of Trauma and Disability Medicine
